Change from baseline AM PEFR (%) (duration 44 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in change from baseline AM PEFR (%) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).
1 finding from 1 review
Asthma control · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in proportion of asthma control days over the period (duration 44 to 52… compared with daily ICS (moderate certainty).
1 finding from 1 review
Change from baseline mean daily use of β2‐agonists (puffs/day) (duration 24 to 44 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in change from baseline mean daily use of β2‐agonists (puffs/day)… compared with daily ICS (moderate certainty).
1 finding from 1 review
Change in height · Children and adults with persistent asthma.
Intermittent 'as needed' ICS probably leads to higher change in height (cm) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).
1 finding from 1 review
Leaving the study early · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in overall withdrawals (duration 12 to 52 weeks) compared with daily ICS (low certainty).
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Pneumonia · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Exacerbations · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Symptoms of dyspnoea · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Adverse events: candidiasis · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
It is very uncertain whether beclometasone changes adverse events: candidiasis compared with placebo (very low certainty).
1 finding from 1 review
Withdrawal (all‐cause) · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
Beclometasone showed no clear difference in withdrawal (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Mortality (all‐cause) (dichotomous Peto method) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
It is very uncertain whether beclometasone/LABA changes mortality (all‐cause) (dichotomous Peto method) compared with LABA (very low certainty).
1 finding from 1 review
Pneumonia · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in pneumonia: participants with at least one (dichotomous Peto odds… compared with LABA (low certainty).
1 finding from 1 review
Exacerbations · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in exacerbations: participants with at least one (dichotomous) compared with LABA (moderate certainty).
1 finding from 1 review
Change in quality of life: SGRQ Scale: 0 to 100 · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Adverse events: candidiasis · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Withdrawal (all‐cause) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in withdrawal (all‐cause) compared with LABA (moderate certainty).
1 finding from 1 review
FEV1 · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Mortality (all‐cause) (dichotomous Peto method) · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
It is very uncertain whether beclometasone changes mortality (all‐cause) (dichotomous Peto method) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Symptom scores Asthma Control Questionnaire (ACQ) ‐ 6‐item version Mean differences in scores at 6 months · patients with clinician‐diagnosed asthma
1 finding from 1 review